Effect of Clinical Pharmacists Participating in the Medication Management of Gynecological Clinical Pathway Under DRGs Payment Mode
Objective To investigate the effect of clinical pharmacists participating in medication management of gynecological clinical pathway under the diagnosis-related groups(DRGs)payment model.Methods A total of 175 patients enrolled in the gynecological clinical pathway in the hospital from January 2020 to September 2023 were selected and divided into the control group(85 cases)and the intervention group(90 cases)based on whether the clinical pharmacist participating in medication management.The patients in the two groups received the DRGs payment model,the patients in the control group received no intervention,while the patients in the intervention group received clinical pharmacist's medication management.Results The hospitalization time of the patients in the intervention group was significantly shorter than that in the control group(P<0.05),and the hospitalization expenses,the drug costs,the drug types,the incidence of adverse drug reactions,the types,and drug costs of prophylactic use of antibiotics and auxiliary drugs in the intervention group were significantly lower than those in the control group(P<0.05).The total qualified rate of clinical pathway case review in the intervention group was 88.98%,which was significantly higher than 70.59%in the control group(P<0.05).The irrational drug use rate in the intervention group was 7.78%,which was significantly lower than 21.18%in the control group(P<0.05).Conclusion Based on the DRGs payment mode,clinical pharmacists participating in the medication management of the gynecological clinical pathway can ensure clinical efficacy,reduce patient hospitalization and drug costs,improve the overall pass rate of clinical pathway case reviews,and promote rational drug use.
DRGs payment modeclinical pharmacistgynecological clinical pathwayrational drug usepharmaceutical management
万方数据
维普
